Prescription-Based Testing Segment to Register Higher CAGR During 2021–2028
According to our new research study on “Point of Care Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Prescription Mode, and End User,” the market is expected to reach US$ 82,958.3 million by 2028 from US$ 36,000.4 million in 2021; it is estimated to grow at a CAGR of 12.7% from 2021 to 2028. The report highlights trends prevailing in the market, and the factors driving and hindering the market growth. The market growth is primarily attributed to increase in prevalence of infectious diseases, product developments and launches, and rise in number of CLIA-waived POC tests. However, product recalls are expected to hamper the market growth.
Based on prescription mode, the point of care diagnostics market is bifurcated into prescription-based testing and OTC testing. In 2020, the prescription-based testing segment held a larger share of the market and is expected to register a higher CAGR during the forecast period. The growth of this segment is mainly attributed to the increasing incidence and prevalence of lifestyle diseases and the lack of awareness on OTC POCT devices in developing nations.
The point of care diagnostics market is witnessing substantial growth amid the COVID-19 pandemic. Certain factors such as sudden rise in coronavirus infections and exponential growth in COVID-19 diagnostic kits played a prominent role in the growth of the point of care diagnostics market during the pandemic. In addition, the growing demand for rapid test kits for faster diagnosis at public places is also estimated to have a positive impact on the market growth.
F. HOFFMANN-LA ROCHE LTD.; Danaher; BIO-RAD LABORATORIES INC.; Abbott; Johnson and Johnson Services, Inc.; Siemens AG; BD; BioMerieux SA; Polymer Technology Systems, Inc. (PTS); and Nova Biomedical are among the leading companies operating in the point of care diagnostics market.
Point of Care Diagnostics Market Analysis, Growth, Share - 2028
Download Free SamplePoint of Care Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Glucose Monitoring Products, Infectious Disease Testing Products, Cardiometabolic Testing Products, Pregnancy and Fertility Testing Products, Coagulation Testing Products, Tumor/Cancer Marker Testing Products, Cholesterol Testing Products, Urinalysis Testing Products, Hematology Testing Products, and Other POC Products), Prescription Mode (Prescription-Based Testing and OTC Testing), and End User (Professional Diagnostic Centers, Home Care, Research Laboratories, and Others), and Geography
The report segments point of care diagnostics market as follows:
By Product
- Glucose Monitoring
- Infectious Disease Testing
- HIV Testing
- Influenza Testing
- Sexually Transmitted Disease (STD) Testing
- Hepatitis C Testing
- Healthcare-Associated Infection (HAI) Testing
- Tropical Disease Testing
- Respiratory Infection Testing
- Other Infectious Disease Testing
- Cardiometabolic Testing
- Pregnancy and Fertility Testing
- Coagulation Testing
- Tumor/Cancer Marker Testing
- Cholesterol Testing
- Urinalysis Testing
- Hematology Testing
- Other POC Products
By Prescription Mode
- Prescription-Based Testing
- OTC Testing
By End User
- Professional Diagnostic Centers
- Hospitals
- Clinical Laboratories
- Outpatient Healthcare
- Ambulatory Care Settings
- Home Care
- Research Laboratories
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- Japan
- Australia
- South Korea
- Rest of APAC
- Middle East and Africa (MEA)
- Saudi Arabia
- UAE
- South Africa
- Rest of MEA
- South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com